Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression

A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine. Chronic mild stress (CMS) provides a valid model of depression; the Wistar-Kyoto (WKY) rat is considered to be nonresponsive to antidepressant drugs. Here, we applied CMS to WKY rats. WKY and Wistar rats were exposed to CMS, then treated with saline, imipramine, citalopram or venlafaxine. After 5 weeks of CMS and 3 weeks of drug treatment, all WKY groups were implanted unilaterally with DBS electrodes in the prefrontal cortex, and examined in sucrose intake, elevated plus maze (EPM; decreased entries and time in the open arms) and novel object recognition (decreased exploration) tests, following 2×2 h of DBS. CMS decreased sucrose intake, open arm entries on the EPM, and object recognition. Relative to Wistars, WKY rats showed evidence of increased emotionality in the EPM and novel object recognition tests, and a greater impact of CMS on body weight gain and open arm entries. Wistars responded to drug treatment with an increase in sucrose intake but WKY were nonresponsive to drug treatment on all three behavioural tests. With one exception, DBS reversed the anhedonic, anxiogenic and dyscognitive effects of CMS in all groups of WKY rats. In a further experiment, subacute ketamine (10 mg/kg) also normalized behaviour on all three tests. We conclude that WKY rats subjected to CMS meet all four criteria for a valid model of TRD, and provide a basis for studying the mechanism of action of DBS.

[1]  M. Papp,et al.  Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression , 2018, Journal of psychopharmacology.

[2]  D. Abrous,et al.  Inducing a long-term potentiation in the dentate gyrus is sufficient to produce rapid antidepressant-like effects , 2018, Molecular Psychiatry.

[3]  M. Febo,et al.  MEMRI reveals altered activity in brain regions associated with anxiety, locomotion, and cardiovascular reactivity on the elevated plus maze in the WKY vs SHR rats , 2017, Brain Imaging and Behavior.

[4]  M. Papp,et al.  P.2.a.004 Effects of deep brain stimulation of the medial prefrontal cortex in two animal models of treatment-resistant depression , 2017, European Neuropsychopharmacology.

[5]  M. Kameda,et al.  Hippocampal neurogenesis of Wistar Kyoto rats is congenitally impaired and correlated with stress resistance , 2017, Behavioural Brain Research.

[6]  A. Csoka,et al.  Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants. , 2017, Drug and alcohol dependence.

[7]  M. Papp,et al.  Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment` , 2017, Psychopharmacology.

[8]  M. Sadananda,et al.  Anxiety- and depressive-like profiles during early- and mid-adolescence in the female Wistar Kyoto rat , 2017, International Journal of Developmental Neuroscience.

[9]  M. Papp,et al.  Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression , 2017, Behavioural pharmacology.

[10]  J. Kelly,et al.  Sex differences and similarities in depressive- and anxiety-like behaviour in the Wistar-Kyoto rat , 2016, Physiology & Behavior.

[11]  R. Servatius,et al.  Exposure to morphine-associated cues increases mu opioid receptor mRNA expression in the nucleus accumbens of Wistar Kyoto rats , 2016, Behavioural Brain Research.

[12]  P. Willner,et al.  The chronic mild stress (CMS) model of depression: History, evaluation and usage , 2016, Neurobiology of Stress.

[13]  M. Papp,et al.  Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats , 2016, Psychopharmacology.

[14]  C. Bielajew,et al.  Environmental manipulation affects depressive-like behaviours in female Wistar-Kyoto rats , 2015, Behavioural Brain Research.

[15]  P. Willner,et al.  Treatment-resistant depression: are animal models of depression fit for purpose? , 2015, Psychopharmacology.

[16]  O. Wiborg,et al.  Presynaptic Plasticity as a Hallmark of Rat Stress Susceptibility and Antidepressant Response , 2015, PloS one.

[17]  Y. Temel,et al.  Electrical stimulation alleviates depressive-like behaviors of rats: investigation of brain targets and potential mechanisms , 2015, Translational Psychiatry.

[18]  P. Philippot,et al.  Depression: from psychopathology to pathophysiology , 2015, Current Opinion in Neurobiology.

[19]  A. Grace,et al.  Restoring Mood Balance in Depression: Ketamine Reverses Deficit in Dopamine-Dependent Synaptic Plasticity , 2014, Biological Psychiatry.

[20]  H. Mayberg,et al.  Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression , 2014, Biological Psychiatry.

[21]  P. Willner,et al.  Resistance to antidepressant drugs: the case for a more predisposition-based and less hippocampocentric research paradigm , 2014, Behavioural pharmacology.

[22]  Collin Challis,et al.  Antidepressant-like Effects of Cortical Deep Brain Stimulation Coincide With Pro-neuroplastic Adaptations of Serotonin Systems , 2014, Biological Psychiatry.

[23]  S. Clinton,et al.  Learned helplessness and social avoidance in the Wistar-Kyoto rat , 2014, Front. Behav. Neurosci..

[24]  Paul E. Holtzheimer,et al.  Deep brain stimulation in the treatment of depression , 2014, Dialogues in clinical neuroscience.

[25]  T. Peters,et al.  Prevalence of treatment-resistant depression in primary care: cross-sectional data. , 2013, The British journal of general practice : the journal of the Royal College of General Practitioners.

[26]  P. Willner,et al.  The neurobiology of depression and antidepressant action , 2013, Neuroscience & Biobehavioral Reviews.

[27]  G. Freedman,et al.  Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.

[28]  Y. Tizabi,et al.  Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR , 2013, Psychopharmacology.

[29]  C. Hendrie,et al.  The failure of the antidepressant drug discovery process is systemic , 2013, Journal of psychopharmacology.

[30]  Sergi G. Costafreda,et al.  Predictive neural biomarkers of clinical response in depression: A meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies , 2013, Neurobiology of Disease.

[31]  E. Dommett,et al.  Appetitive and consummative responding for liquid sucrose in the spontaneously hypertensive rat model of attention deficit hyperactivity disorder , 2013, Behavioural Brain Research.

[32]  G. Griebel,et al.  Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543 , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  B. Gorzalka,et al.  Neurobiology of chronic mild stress: Parallels to major depression , 2012, Neuroscience & Biobehavioral Reviews.

[34]  K. Manaye,et al.  Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar–Kyoto rats , 2012, Neuroscience.

[35]  M. Papp Models of Affective Illness: Chronic Mild Stress in the Rat , 2012, Current protocols in pharmacology.

[36]  Clement Hamani,et al.  Deep Brain Stimulation Reverses Anhedonic-Like Behavior in a Chronic Model of Depression: Role of Serotonin and Brain Derived Neurotrophic Factor , 2012, Biological Psychiatry.

[37]  Ashwini Sharan,et al.  An Evaluation of Neuroplasticity and Behavior After Deep Brain Stimulation of the Nucleus Accumbens in an Animal Model of Depression , 2011, Neurosurgery.

[38]  J. Lépine,et al.  The increasing burden of depression , 2011, Neuropsychiatric disease and treatment.

[39]  M. Thase Treatment-resistant depression: prevalence, risk factors, and treatment strategies. , 2011, The Journal of clinical psychiatry.

[40]  Clement Hamani,et al.  The Subcallosal Cingulate Gyrus in the Context of Major Depression , 2011, Biological Psychiatry.

[41]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[42]  K. Manaye,et al.  Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[43]  A. Weller,et al.  Two different putative genetic animal models of childhood depression—A review , 2009, Progress in Neurobiology.

[44]  H. Mayberg Targeted electrode-based modulation of neural circuits for depression. , 2009, The Journal of clinical investigation.

[45]  Glenda M. MacQueen,et al.  Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder , 2008, Biological Psychiatry.

[46]  Jason B. Tanenbaum,et al.  Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine , 2008, Physiology & Behavior.

[47]  C. Nemeroff,et al.  Prevalence and management of treatment-resistant depression. , 2007, The Journal of clinical psychiatry.

[48]  T. Thykjær,et al.  Molecular Pathways Associated with Stress Resilience and Drug Resistance in the Chronic Mild Stress Rat Model of Depression—a Gene Expression Study , 2007, Journal of Molecular Neuroscience.

[49]  J. Enghild,et al.  Proteomic Investigation of the Ventral Rat Hippocampus Links DRP-2 to Escitalopram Treatment Resistance and SNAP to Stress Resilience in the Chronic Mild Stress Model of Depression , 2007, Journal of Molecular Neuroscience.

[50]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[51]  G. Churchill,et al.  Test- and behavior-specific genetic factors affect WKY hypoactivity in tests of emotionality , 2006, Behavioural Brain Research.

[52]  David A. Morilak,et al.  Role of brain norepinephrine in the behavioral response to stress , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  M. Ivarsson,et al.  Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. , 2005, European journal of pharmacology.

[54]  D. Overstreet,et al.  Reward and anxiety in genetic animal models of childhood depression , 2005, Behavioural Brain Research.

[55]  R. D. L. Garza Wistar Kyoto rats exhibit reduced sucrose pellet reinforcement behavior and intravenous nicotine self-administration , 2005, Pharmacology Biochemistry and Behavior.

[56]  B. Ravnkilde,et al.  Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.

[57]  R. D. L. Garza,et al.  A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression , 2004, Brain Research.

[58]  W. Paré,et al.  Strain-dependent modification of behavior following antidepressant treatment , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[59]  P. A. Mason,et al.  Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders , 2002, Neuroscience.

[60]  P. Willner,et al.  The validity of animal models of predisposition to depression. , 2002, Behavioural pharmacology.

[61]  I. Lucki,et al.  Amplified behavioral and endocrine responses to forced swim stress in the Wistar–Kyoto rat , 2002, Psychoneuroendocrinology.

[62]  J. Greden The burden of disease for treatment-resistant depression. , 2001, The Journal of clinical psychiatry.

[63]  W. Paré Investigatory behavior of a novel conspecific by Wistar Kyoto, Wistar and Sprague-Dawley rats , 2000, Brain Research Bulletin.

[64]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[65]  F. Chaouloff,et al.  Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats , 1999, Neuropharmacology.

[66]  I. Lucki,et al.  Strain Differences in the Behavioral Effects of Antidepressant Drugs in the Rat Forced Swimming Test , 1997, Neuropsychopharmacology.

[67]  Á. Pazos,et al.  Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants? , 1997, European journal of pharmacology.

[68]  P. Willner Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation , 1997, Psychopharmacology.

[69]  F. Chaouloff,et al.  Behavioral Reactivity to Social and Nonsocial Stimulations: A Multivariate Analysis of Six Inbred Rat Strains , 1997, Behavior genetics.

[70]  A. Armario,et al.  Comparison of the behavioural and endocrine response to forced swimming stress in five inbred strains of rats , 1995, Psychoneuroendocrinology.

[71]  W. Paré,et al.  Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats , 1994, Brain Research.

[72]  W. Paré Stress ulcer susceptibility and depression in Wistar Kyoto (WKY) rats , 1989, Physiology & Behavior.

[73]  C. Gentsch,et al.  Genetic and environmental influences on behavioral and neurochemical aspects of emotionality in rats , 1988, Experientia.

[74]  Michael X. Cohen,et al.  Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression , 2008, Neuropsychopharmacology.

[75]  P. Willner,et al.  The validity of animal models of depression , 2004, Psychopharmacology.

[76]  Y. Michotte,et al.  Serotonin Reuptake Inhibition by Citalopram in Rat Strains Differing for Their Emotionality , 2000, Neuropsychopharmacology.